XELJANZ® (tofacitinib citrate) Receives Marketing Authorization in the European Union for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis

Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has approved XELJANZ® …

Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has approved XELJANZ^® ...